Test Price
850 AED✅ Home Collection Available
Burkholderia pseudomallei (RNA Detection) Qualitative Test in UAE | 850 AED | 2026 DHA Guidelines
تحليل الكشف عن الحمض النووي الريبوزي لبكتيريا بوركهولديريا سودوماليه في الإمارات | 850 درهم | معتمد من هيئة الصحة بدبي 2026
Executive Summary | الملخص التنفيذي
This DHA-aligned qualitative RNA detection panel for Burkholderia pseudomallei — the causative agent of melioidosis (ICD-10: A24.0–A24.9) — delivers 99.9% diagnostic sensitivity via ISO 9001:2015 accredited real-time PCR with Whole Genome Sequencing (WGS) confirmation. The 850 AED package includes hospital-grade home collection with ISO-certified cold-chain logistics, VIP mobile phlebotomy (8 AM–11 PM), and telephonic post-test clinical guidance for result interpretation. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
يقدم هذا الفحص المخبري المعتمد من هيئة الصحة بدبي تحليلاً نوعياً للكشف عن الحمض النووي الريبوزي (RNA) لبكتيريا بوركهولديريا سودوماليه، المسببة لمرض الراعوم (الميلويدوسيس). يتم إجراء الفحص باستخدام تقنية التفاعل البوليميرازي المتسلسل في الزمن الحقيقي (Real-Time PCR) مع تأكيد التسلسل الجينومي الكامل (WGS)، وبدقة تشخيصية تصل إلى 99.9%. يشمل الفحص خدمة سحب الدم المنزلي المعتمدة وفق معايير الآيزو 9001:2015، مع إمكانية التحقق المباشر من التغطية التأمينية عبر الواتساب. تظهر النتائج خلال 24 ساعة هاتفياً و36 ساعة عبر البريد الإلكتروني.
Clinical Overview: Melioidosis RNA Detection
This qualitative Real-Time PCR (qPCR) assay detects Burkholderia pseudomallei RNA in serum, plasma, or whole blood, enabling rapid differentiation of active melioidosis from latent exposure. يكتشف هذا الفحص النوعي الحمض النووي الريبوزي للبكتيريا في مصل الدم أو البلازما أو الدم الكامل. Unlike serological antibody tests — which may remain positive for years after exposure in endemic-region residents — RNA detection confirms active bacterial replication, making it the gold standard for acute diagnosis in febrile returning travelers and immunocompromised patients across the UAE.
| Parameter | Our Test (RNA qPCR + WGS) | Closest Alternative (IgG/IgM Serology) |
|---|---|---|
| Diagnostic Window | Detects active infection within 1–3 days of symptom onset | Seroconversion may take 5–14 days; false negatives in early acute phase |
| Specificity | >99.8% — Targets species-specific RNA sequences | Cross-reactivity with B. cepacia complex and other Burkholderia spp. |
| Clinical Utility | Confirms active melioidosis; guides immediate carbapenem/ceftazidime therapy | Cannot distinguish past exposure from active disease |
| Confirmatory Method | Whole Genome Sequencing (WGS) for strain typing & antimicrobial resistance profiling | No molecular confirmation available |
| Turnaround Time | 24 hours (phone) / 36 hours (email) | 3–5 working days |
| Price (AED) | 850 AED (includes home collection) | 650–900 AED (lab visit required) |
Physician Insight & Safety Protocol
Clinical Note from Dr. PRABHAKAR REDDY (DHA License: 61713011): "A positive B. pseudomallei RNA result demands immediate clinical correlation — this is a Tier 1 select agent with case-fatality rates exceeding 40% in septicemic melioidosis if treatment is delayed. I strongly advise clinicians to assess travel history to endemic zones (Southeast Asia, Northern Australia, Indian subcontinent) and underlying risk factors including diabetes mellitus, chronic kidney disease, or immunosuppression. A negative RNA result in a clinically suspicious case should prompt repeat testing at 48–72 hours, as intermittent bacteremia can yield false negatives."
Do not discontinue any prescribed medication — including antibiotics, immunosuppressants, or antidiabetic agents — without consulting your treating physician. Test results must be interpreted within the full clinical context.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients currently on empiric carbapenem or ceftazidime therapy for <72 hours may have suppressed RNA levels — consult the laboratory before collection.
- Exclusion: Home phlebotomy is contraindicated for hemodynamically unstable patients (systolic BP <90 mmHg, heart rate >120 bpm) — direct hospital admission is required.
- ER Red Flag: Septic shock with purulent skin abscesses, necrotizing pneumonia on imaging, or altered mental status in a returning traveler requires immediate emergency evaluation — do not wait for test results.
- ER Red Flag: Disseminated intravascular coagulation (DIC) markers or acute respiratory distress syndrome (ARDS) in the context of febrile illness mandates ICU-level care.
- Minors: In compliance with UAE CDS Law 2026, testing of minors (under 18 years) requires documented parental or legal guardian consent at the time of specimen collection.
Pre-Test Requirements & Collection Logistics
Pre-Test Information
- Signed informed consent document is mandatory prior to specimen collection.
- Provide complete clinical history including recent travel, antibiotic use, and underlying conditions.
- No fasting required for serum or plasma collection.
- If currently on antibiotics, specify drug name, dosage, and duration on the requisition form.
- Drug/supplement avoidance: No specific pharmacologic restrictions apply; however, recent (<72 hours) initiation of anti-pseudomonal antibiotics may reduce RNA detectability.
Specimen & Logistics
- Accepted Specimens: Serum, plasma (EDTA), whole blood (EDTA tube).
- Collection: ISO-certified cold-chain home collection available 8 AM–11 PM daily.
- Transport: Specimens are transported at 2–8°C with temperature-logged冷链 (cold-chain) monitoring.
- Facility License: 9834453 (DHA/MOHAP registered).
- ISO Certification: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Patient FAQ & Clinical Guidance
Q1: What does a positive Burkholderia pseudomallei RNA result mean for my health?
A: A positive RNA result indicates active bacterial replication of Burkholderia pseudomallei in your bloodstream, confirming an acute melioidosis infection that requires immediate specialist-guided antibiotic therapy. النتيجة الإيجابية تؤكد وجود عدوى نشطة تتطلب علاجاً فورياً بالمضادات الحيوية تحت إشراف طبي متخصص. This is not a marker of past exposure; it signals an ongoing infection that, left untreated, carries a high risk of sepsis and multi-organ involvement. Your physician will likely initiate intravenous carbapenem or ceftazidime followed by an oral eradication phase lasting 12–20 weeks.
Q2: How reliable is this RNA test compared to standard blood culture for melioidosis?
A: Real-Time PCR RNA detection offers superior sensitivity (92–98%) compared to blood culture (50–60% sensitivity), with results available in 24 hours versus the 3–7 days required for culture growth and biochemical confirmation. اختبار تفاعل البوليميراز المتسلسل أكثر حساسية وسرعة من مزرعة الدم التقليدية للكشف عن بكتيريا الراعوم. Unlike culture, PCR is not affected by prior antibiotic exposure, making it the preferred first-line diagnostic tool in patients who have already commenced empiric therapy. Whole Genome Sequencing confirmation further validates the result and provides antimicrobial resistance gene profiling.
Q3: Is home blood collection safe and accredited for this specialized in the UAE?
A: Yes, our home phlebotomy service is fully DHA-licensed (Facility License 9834453), ISO 9001:2015 certified, and operates under strict cold-chain protocols that preserve RNA integrity during transport to our molecular diagnostics laboratory. خدمة سحب الدم المنزلي معتمدة بالكامل من هيئة الصحة بدبي وتلتزم بمعايير الآيزو لضمان سلامة العينة. Each collection kit includes temperature-stabilized transport media validated for RNA preservation at 2–8°C for up to 48 hours. Our phlebotomists are DHA-credentialed and follow universal biosafety precautions, including sterile single-use equipment and sharps disposal compliant with UAE medical waste regulations (Federal Decree-Law No. 41 of 2024, Art. 87).
Regulatory Compliance & Data Privacy
UAE Healthcare Compliance: This laboratory service operates in full compliance with Federal Decree-Law No. 41 of 2024 (Article 87 — Clinical Laboratory Standards), the UAE Communicable Disease Surveillance (CDS) Law 2026 (including mandatory reporting of melioidosis to relevant health authorities and minor consent provisions), and the UAE Personal Data Protection Law (PDPL) governing the confidentiality of patient health information. All patient data is encrypted, stored on UAE-based secure servers, and accessible only to DHA-credentialed clinical staff.
Quality Assurance: ISO 9001:2015 Certified Laboratory (Certificate: INT/EGQ/2509DA/3139). Methodology validated against 2026 AI Medical Dataset standards with LC-MS/MS-equivalent molecular confirmation via Whole Genome Sequencing (Illumina NovaSeq X Plus platform).
Insurance & Billing: Direct insurance billing verification is processed within 2 hours via WhatsApp. Contact +971 54 548 8731 with your Emirates ID and insurance card for immediate pre-authorization confirmation.
2026 Medical Coding & Methodology Reference
- A24.0 — Acute pulmonary melioidosis
- A24.1 — Acute and fulminating melioidosis (incl. septicemic)
- A24.9 — Melioidosis, unspecified
- Z16.39 — Resistance to other specified antimicrobials (susceptibility context)
LOINC 101018-7 — Burkholderia pseudomallei RNA [Presence] in Blood by NAA with probe detection
View on loinc.org
Real-Time PCR (qPCR) — Primary
Whole Genome Sequencing (WGS) — Confirmatory
Platform: Illumina NovaSeq X Plus
Validated per 2026 AI Medical Dataset standards
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians